|
1
|
Shirasaka T, Shimamato Y, Ohshimo H, et
al: Development of a novel form of an oral 5-fluorouracil
derivative (S-1) directed to the potentiation of the tumor
selective cytotoxicity of 5-fluorouracil by two biochemical
modulators. Anticancer Drugs. 7:548–557. 1996.
|
|
2
|
Diasio RB: Clinical implications of
dihydropyrimidine dehydrogenase inhibition. Oncology (Williston
Park). 13(Suppl 3): 17–21. 1999.
|
|
3
|
Yamada Y, Hamaguchi T, Goto M, et al:
Plasma concentrations of 5-fluorouracil and F-beta-alanine
following oral administration of S-1, a dihydropyrimidine
dehydrogenase inhibitory fluoropyrimidine, as compared with
protracted venous infusion of 5-fluorouracil. Br J Cancer.
89:816–820. 2003.
|
|
4
|
Ohtsu A, Baba H, Sakata Y, et al: Phase II
study of S-1, a novel oral fluoropyrimidine derivative, in patients
with metastatic colorectal carcinoma. S-1 Cooperative Colorectal
Carcinoma Study Group. Br J Cancer. 83:141–145. 2000.
|
|
5
|
Shirao K, Ohtsu A, Takada H, et al: Phase
II study of oral S-1 for treatment of metastatic colorectal
carcinoma. Cancer. 100:2355–2361. 2004.
|
|
6
|
Muro K, Boku N, Shimada Y, et al:
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid
plus irinotecan (FOLFIRI) as second-line chemotherapy for
metastatic colorectal cancer: a randomised phase 2/3
non-inferiority study (FIRIS study). Lancet Oncol. 11:853–860.
2010.
|
|
7
|
Sakuramoto S, Sasako M, Yamaguchi T, et
al; ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with
S-1, an oral fluoropyrimidine. N Engl J Med. 357:1810–1820.
2007.
|
|
8
|
Sasako M, Sakuramoto S, Katai H, et al:
Five-year outcomes of a randomized phase III trial comparing
adjuvant chemotherapy with S-1 versus surgery alone in stage II or
III gastric cancer. J Clin Oncol. 29:4387–4393. 2011.
|
|
9
|
Ogawa M, Watanabe M, Kobayashi T, et al:
Feasibility study of S-1 adjuvant chemotherapy in patients with
colorectal cancer. Int J Clin Oncol. 18:678–683. 2013.
|
|
10
|
Salonga D, Danenberg KD, Johnson M, et al:
Colorectal tumors responding to 5-fluorouracil have low gene
expression levels of dihydropyrimidine dehydrogenase, thymidylate
synthase, and thymidine phosphorylase. Clin Cancer Res.
6:1322–1327. 2000.
|
|
11
|
Popat S, Matakidou A and Houlston RS:
Thymidylate synthase expression and prognosis in colorectal cancer:
a systematic review and meta-analysis. J Clin Oncol. 22:529–536.
2004.
|
|
12
|
Sobin LH and Wittekind Ch: TNM
Classification of Malignant Tumors. 6th edition. Wiley-Liss, Inc;
New York, NY: 2002
|
|
13
|
Bonner RF, Emmert-Buck M, Cole K, et al:
Laser capture microdissection: molecular analysis of tissue.
Science. 278:14811997.
|
|
14
|
Lord RV, Salonga D, Danenberg KD, et al:
Telomerase reverse transcriptase expression is increased early in
the Barrett’s metaplasia, dysplasia, adenocarcinoma sequence. J
Gastrointest Surg. 4:135–142. 2000.
|
|
15
|
Satoh T and Sakata Y: S-1 for the
treatment of gastrointestinal cancer. Expert Opin Pharmacother.
13:1943–1959. 2012.
|
|
16
|
Shirasaka T, Shimamoto Y and Fukushima M:
Inhibition by oxonic acid of gastrointestinal toxicity of
5-fluorouracil without loss of its antitumor activity in rats.
Cancer Res. 53:4004–4009. 1993.
|
|
17
|
Shirasaka T, Shimamato Y, Ohshimo H, et
al: Development of a novel form of an oral 5-fluorouracil
derivative (S-1) directed to the potentiation of the tumor
selective cytotoxicity of 5-fluorouracil by two biochemical
modulators. Anticancer Drugs. 7:548–557. 1996.
|
|
18
|
Mochizuki I, Takiuchi H, Ikejiri K, et al:
Safety of UFT/LV and S-1 as adjuvant therapy for stage III colon
cancer in phase III trial: ACTS-CC trial. Br J Cancer.
106:1268–1273. 2012.
|
|
19
|
Furukawa T, Yoshimura A, Sumizawa T, et
al: Angiogenic factor. Nature. 356:6681992.
|
|
20
|
Takebayashi Y, Akiyama S, Akiba S, et al:
Clinicopathologic and prognostic significance of an angiogenic
factor, thymidine phosphorylase, in human colorectal carcinoma. J
Natl Cancer Inst. 88:1110–1117. 1996.
|
|
21
|
Nakayama Y, Inoue Y, Nagashima N, et al:
Expression levels of thymidine phosphorylase (TP) and
dihydropyrimidine dehydrogenase (DPD) in patients with
gastrointestinal cancer. Anticancer Res. 25:3755–3761. 2005.
|
|
22
|
Metzger R, Danenberg K, Leichman CG, et
al: High basal level gene expression of thymidine phosphorylase
(platelet-derived endothelial cell growth factor) in colorectal
tumors is associated with nonresponse to 5-fluorouracil. Clin
Cancer Res. 4:2371–2376. 1998.
|
|
23
|
Toi M, Hoshina S, Taniguchi T, et al:
Expression of platelet-derived endothelial cell growth
factor/thymidine phosphorylase in human breast cancer. Int J
Cancer. 64:79–82. 1995.
|
|
24
|
Takebayashi Y, Akiyama S, Akiba S, et al:
Clinicopathologic and prognostic significance of an angiogenic
factor, thymidine phosphorylase, in human coborectal carcinoma. J
Natl Cancer Inst. 88:1110–1117. 1996.
|
|
25
|
Maeda K, Chung YS, Ogawa Y, et al:
Thymidine phosphorylase/platelet-derived endothelial cell growth
factor expression associated with hepatic metastasis in gastric
carcinoma. Br J Cancer. 73:884–888. 1996.
|
|
26
|
Sadahiro S, Suzuki T, Tanaka A, Okada K,
Nagase H and Uchida J: Association of right-sided tumors with high
thymidine phosphorylase gene expression levels and the response to
oral uracil and tegafur/leucovorin chemotherapy among patients with
colorectal cancer. Cancer Chemother Pharmacol. 70:285–291.
2012.
|
|
27
|
Hasegawa S, Seike K, Koda K, et al:
Thymidine phosphorylase expression and efficacy of adjuvant
doxifluridine in advanced colorectal cancer patients. Oncol Rep.
13:621–626. 2005.
|
|
28
|
Salonga D, Danenberg KD, Johnson M, et al:
Colorectal tumors responding to 5-fluorouracil have low gene
expression levels of dihydropyrimidine dehydrogenase, thymidylate
synthase, and thymidine phosphorylase. Clin Cancer Res.
6:1322–1327. 2000.
|
|
29
|
Yoshinare K, Kubota T, Watanabe M, et al:
Gene expression in colorectal cancer and in vitro chemosensitivity
to 5-fluorouracil: a study of 88 surgical specimens. Cancer Sci.
94:633–638. 2003.
|
|
30
|
Nishimura G, Terada I, Kobayashi T, et al:
Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels
in primary colorectal cancer show a relationship to clinical
effects of 5′-deoxy-5-fluorouridine as adjuvant chemotherapy. Oncol
Rep. 9:479–482. 2002.
|
|
31
|
Jensen SA, Vainer B, Witton CJ, Jørgensen
JT and Sørensen JB: Prognostic significance of numeric aberrations
of genes for thymidylate synthase, thymidine phosphorylase and
dihydrofolate reductase in colorectal cancer. Acta Oncol.
47:1054–1061. 2008.
|
|
32
|
Collie-Duguid ES, Johnston SJ, Boyce L, et
al: Thymidine phosphorylase and dihydropyrimidine dehydrogenase
protein expression in colorectal cancer. Int J Cancer. 94:297–301.
2001.
|
